Vicary-Watts R, Hall K, Passmore-Szilagyi O, Zelhof B
Department of Urology, Lancashire Teaching Hospitals, Preston, Lancashire, UK.
Department of Anaesthesiology, Lancashire Teaching Hospitals, Preston, Lancashire, UK.
Br J Pain. 2022 Dec;16(6):632-640. doi: 10.1177/20494637221115926. Epub 2022 Jul 15.
Single-shot spinal diamorphine is becoming common practice in urological surgery to aid post-operative pain; however, its safety and efficacy require investigation. This study is a retrospective analysis of 113 laparoscopic or robotic-assisted nephrectomies over 4 years under one consultant urologist. Data were collected on demographic, pre-operative scores, anaesthesia, surgical information, post-operative outcomes and opioid consumption. Two main groups were established: no spinal diamorphine (NSD) and spinal diamorphine (SD). Four subgroups were then created, separating those who received patient-controlled anaesthesia (PCA) or not: Group 1 [general anaesthetic (GA)]; Group 2 [GA and PCA]; Group 3 [GA and spinal diamorphine] and Group 4 [GA, spinal diamorphine and PCA]. Ninety-eight eligible patients were identified. At 6 hours, pain scores were significantly higher for all non-spinal groups ( < 0.05); at 9 h, pain scores were significantly higher in NSD patients compared to SD ( = 0.026); at 12 h, pain scores were significantly higher for NSD patients compared to SD ( = 0.024), and Group 1 compared to Group 3 ( = 0.023). Total opioid consumption in the first 24 h post-surgery was higher in Group 1 compared to Group 3 ( = 0.024). There was no higher incidence of urinary retention, or any neurological complications reported within the SD patients. The study found a reduction in post-operative pain scores with the use of spinal diamorphine prior to laparoscopic and robotic-assisted nephrectomies. The findings may also suggest that pre-operative spinal diamorphine use can reduce the total volume of opioids administered via other routes in the first 24 h post-operatively. It recommends its routine administration but encourages prospective investigation.
单次注射脊髓吗啡在泌尿外科手术中已成为辅助术后镇痛的常用方法;然而,其安全性和有效性仍需研究。本研究是对一位泌尿外科顾问医生在4年期间进行的113例腹腔镜或机器人辅助肾切除术的回顾性分析。收集了患者的人口统计学资料、术前评分、麻醉、手术信息、术后结果及阿片类药物使用情况。主要分为两个组:未使用脊髓吗啡(NSD)组和使用脊髓吗啡(SD)组。然后又分为四个亚组,区分是否接受患者自控镇痛(PCA):第1组[全身麻醉(GA)];第2组[GA和PCA];第3组[GA和脊髓吗啡];第4组[GA、脊髓吗啡和PCA]。共确定了98例符合条件患者。术后6小时,所有未使用脊髓吗啡组的疼痛评分显著更高(<0.05);术后9小时,NSD患者的疼痛评分显著高于SD患者(=0.026);术后12小时,NSD患者的疼痛评分显著高于SD患者(=0.024),且第1组高于第3组(=0.023)。术后第1个24小时内,第1组的阿片类药物总消耗量高于第3组(=0.024)。SD组患者未出现更高的尿潴留发生率或任何神经并发症报告。研究发现,在腹腔镜和机器人辅助肾切除术前使用脊髓吗啡可降低术后疼痛评分。研究结果还可能表明,术前使用脊髓吗啡可减少术后第1个24小时内通过其他途径给予的阿片类药物总量。研究建议常规使用脊髓吗啡,但鼓励进行前瞻性研究。